IQVIA Holdings Inc. (NYSE:IQV) Shares Sold by BNP Paribas Financial Markets

BNP Paribas Financial Markets cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 13.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 286,082 shares of the medical research company’s stock after selling 42,836 shares during the period. BNP Paribas Financial Markets’ holdings in IQVIA were worth $67,793,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the period. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of IQVIA during the third quarter valued at approximately $147,683,000. 1832 Asset Management L.P. raised its holdings in shares of IQVIA by 472.3% during the second quarter. 1832 Asset Management L.P. now owns 456,335 shares of the medical research company’s stock valued at $96,487,000 after acquiring an additional 376,595 shares during the period. Renaissance Technologies LLC acquired a new stake in shares of IQVIA during the second quarter valued at approximately $70,610,000. Finally, Impax Asset Management Group plc raised its holdings in shares of IQVIA by 19.3% during the second quarter. Impax Asset Management Group plc now owns 1,635,201 shares of the medical research company’s stock valued at $344,998,000 after acquiring an additional 264,555 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Stock Performance

IQV stock opened at $201.44 on Thursday. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76. The company has a market capitalization of $36.56 billion, a price-to-earnings ratio of 26.44, a P/E/G ratio of 2.10 and a beta of 1.51. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The firm has a 50 day moving average of $220.36 and a two-hundred day moving average of $226.57.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Redburn Atlantic started coverage on shares of IQVIA in a report on Monday, October 14th. They set a “buy” rating and a $276.00 price target on the stock. The Goldman Sachs Group dropped their price objective on shares of IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Evercore ISI dropped their price objective on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. Finally, Truist Financial dropped their price objective on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.